Todd James Bixby

Mr. Todd James Bixby


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2023 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
TBTodd James Bixby
Todd James Bixby
CBChristine J. Brittle
Christine J. Brittle
PMPatricia A. Mangan
Patricia A. Mangan
ESEdward A. Stadtmauer
Edward A. Stadtmauer
LKLisa R. Kallenbach
Lisa R. Kallenbach
Introduction Chimeric antigen receptor-T cell (CAR-T) therapy has revolutionized advanced blood cancer treatment. However, preparation, administration, and recovery from these therapies can be complex and burdensome to patients and their care partners. Utilization of an outpatient setting for CAR-T therapy administration could help improve convenience and quality of life. Methods In-depth qualitative interviews were conducted with 18 patients in the USA with relapsed/refractory multiple myeloma or relapsed/refractory diffuse large B-cell lymphoma, 10 of whom had completed investigational or commercially approved CAR-T therapy and 8 of whom had discussed it with their physicians. We aimed to better understand inpatient experiences and patient expectations regarding CAR-T therapy and to ascertain patient perspectives on the possibility of outpatient care. Results CAR-T offers unique treatment benefits, particularly high response rates with an extended treatment-free period. All study participants completing CAR-T were very positive about their inpatient recovery experience. Most reported mild-to-moderate side effects; two experienced severe side effects. All said that they would opt to undergo CAR-T therapy again. Participants felt that the primary advantage of inpatient recovery was immediate access to care and on-going monitoring. Perceived advantages of the outpatient setting were comfort and familiarity. Because immediate access to care was seen as crucial, patients recovering in an outpatient setting would seek either a direct contact person or phone line for assistance if needed. Conclusion As institutions become more experienced with CAR-T therapies, outpatient care may help reduce financial strain. Patient input can help institutions improve the outpatient experience and ensure safety and effectiveness of CAR-T programs.

25 February 2020 in Drugs in Context
Verified
Journal Article
Closed access
AZAndrea Zlatkus
Andrea Zlatkus
TBTodd James Bixby
Todd James Bixby
KGKavitha Goyal
Kavitha Goyal
As numerous biosimilar products are forecast to enter the US market in the coming years, health-system pharmacists will be faced with novel challenges while incorporating them into clinical practice. The current regulatory approval framework and guidance from the US Food and Drug Administration do not address many real-world scenarios that pharmacists will encounter. We provide an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the health-system pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.

13 January 2026 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
RFRafael Fonseca
Rafael Fonseca
SSSurbhi Sidana
Surbhi Sidana
KBKevin C. De Braganca
Kevin C. De Braganca
TLTamar Lengil
Tamar Lengil
AMAhmed Mohamed
Ahmed Mohamed
PVPeter Voorhees
Peter Voorhees
Chimeric antigen receptor-T (CAR-T) cell therapies are highly effective in treating hematologic malignancies. Cases of second primary malignancies (SPMs) have been reported post-treatment, although risk factors remain unclear. This real-world study evaluated predictors of SPMs among patients treated with CAR-T. Patients with multiple myeloma (MM) or lymphoma/leukemia treated with CAR-T were identified from the Komodo Research Database (January 1, 2016-June 30, 2024). Incidences of SPMs and hematologic SPMs were evaluated following CAR-T infusion (index date) and predictors were evaluated 12 months pre-index. LASSO regression was used to identify predictors of SPMs and hematologic SPMs, separately. Multivariate Cox regression was used to assess the magnitude and direction of each predictor. Among 2,609 patients receiving CAR-T (MM: 683, lymphoma/leukemia: 1,926) and over a median follow-up of 14.5 months, the incidences of SPMs and hematologic SPMs were 11.8% and 5.0%, respectively (0.3% for peripheral T-cell lymphoma). Median time-to-event was approximately 8 months for SPMs and hematologic SPMs. Adjusting for other predictors in the models, there was no association between CAR-T indicated for MM versus lymphoma/leukemia and the risk of SPMs (hazard ratio: 0.85, P = .32). Relative to lymphoma/leukemia, MM was associated with a significantly lower risk of hematologic SPMs (hazard ratio: 0.24, P < .05). This study found no association between CAR-Ts used in MM versus lymphoma/leukemia and the risk of subsequent SPMs, while a lower risk of hematologic SPMs was observed in patients with MM. T-cell malignancies were infrequent. Ongoing research into potential risk factors of SPMs following CAR-T could help inform individualized management strategies.

26 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TGTara K Gregory
Tara K Gregory
KBKevin C. De Braganca
Kevin C. De Braganca
VAVictoria Alegria
Victoria Alegria
MPMatthew Perciavalle
Matthew Perciavalle
RPRavi Potluri
Ravi Potluri
ZQZaina P. Qureshi
Zaina P. Qureshi
Background/Objectives: Ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma is typically administered inpatient (IP) to monitor for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Because cilta-cel toxicities are typically delayed, outpatient (OP) administration (infusion and early monitoring) is being explored. We synthesized available evidence on OP and IP administration. Methods: MEDLINE, Embase, and Cochrane Library were searched from inception to 5 August 2025, supplemented by conference and gray literature searches. Eligible studies of adults with multiple myeloma receiving cilta-cel reported efficacy, safety, resource use, costs, and/or quality-of-life outcomes; findings were synthesized descriptively due to heterogeneity. Results: Seventy-four records (56 studies) were included; 90 patients received OP cilta-cel. OP clinical evidence (primarily three real-world studies) showed high response rates (ORR: 95%; median follow-up 4.6 months) and reported 1-year PFS and OS of 86% and 96%. In IP studies, median ORR was 91%, with median 1-year PFS 76% and median 1-year OS 85%. Any-grade CRS and ICANS occurred in 79–84% and 17–22% of OP patients (largely low grade); IP cohorts reported a median ICANS incidence of 17% (range 5–23%). Most OP patients were later hospitalized (86–93%), but stays were shorter (median 4–6.5 days) than in an IP cohort (median 19 days). Comparisons were unadjusted and may reflect selection differences. One modeling-based economic analysis estimated savings of ~$19,000 per OP-treated patient. Conclusions: OP cilta-cel appears feasible for selected patients and may reduce costs without compromising outcomes. Findings are descriptive and hypothesis-generating and prospective multicenter studies are needed to define long-term safety, durability, quality of life, and cost-effectiveness.

1 July 2026 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
MJMurali Janakiram
Murali Janakiram
SGSabyasachi Ghosh
Sabyasachi Ghosh
VAVictoria Alegria
Victoria Alegria
MPMatthew Perciavalle
Matthew Perciavalle
BEBruno Emond
Bruno Emond
DDDanai Dima
Danai Dima
Background: Ciltacabtagene autoleucel (cilta-cel) was approved for patients with relapsed or refractory multiple myeloma who received 1–3 prior lines of therapy in April 2024. Although traditionally administered inpatient (IP), there is an increasing trend in outpatient (OP) cilta-cel administration. However, few studies have quantified the healthcare resource utilization (HCRU) and cost implications of OP versus IP administration in clinical practice. Aim: To compare HCRU and costs following OP versus IP administration of cilta-cel among patients with relapsed or refractory multiple myeloma after 1–3 prior lines of therapy. Materials & methods: This retrospective observational study used the Loopback Analytics electronic medical records database (28 February 2017 to 30 June 2025). We classified patients into OP or IP cohorts. All-cause and multiple myeloma-related HCRU and per-patient-per-month imputed costs were compared over 30 and 90 days post-infusion. Results: There were 99 patients included (OP: 37; IP: 62). In the first 30 days post-infusion, 40.5% of the OP cohort did not require IP admission. Compared with the IP cohort, the OP cohort had significantly lower all-cause IP days (adjusted incidence rate ratio: 0.31; p < 0.001) and significantly lower all-cause IP-related imputed costs (adjusted mean difference: -$39,786; p < 0.001). Results were consistent over the first 90 days post-infusion and for multiple myeloma related HCRU and costs. Overall, OP administration was associated with an estimated cost savings of approximately $40,000 and $53,000 per patient in the first 30 and 90 days post-infusion, respectively. Conclusion: OP administration of cilta-cel was associated with significantly lower IP resource utilization and imputed costs over the first 3 months post-infusion relative to IP administration, supporting the potential economic value and adoption of OP cilta-cel delivery.